183 related articles for article (PubMed ID: 16537661)
21. From TROPHY with pride.
Julius S; Schork A; Egan BM
Am J Hypertens; 2007 Mar; 20(3):342-3; author reply 343-5. PubMed ID: 17324750
[No Abstract] [Full Text] [Related]
22. CHARM shows benefits of Atacand for symptomatic heart failure.
Cardiovasc J S Afr; 2003; 14(5):284. PubMed ID: 14664231
[No Abstract] [Full Text] [Related]
23. Possible benefits of azilsartan compared with other angiotensin II type 1 receptor blockers.
Miura S; Saku K
Hypertens Res; 2014 Sep; 37(9):799-800. PubMed ID: 25007763
[No Abstract] [Full Text] [Related]
24. [Angiotensin receptor antagonist for therapy of patients with hypertension].
Rakugi H; Ogihara T
Nihon Rinsho; 1997 Aug; 55(8):2075-80. PubMed ID: 9284426
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of hypertension can do more. Using chances for organ protection].
MMW Fortschr Med; 2006 Nov; 148(45):58-9. PubMed ID: 17615753
[No Abstract] [Full Text] [Related]
26. CHARM shows improvement in NYHA functional class with candesartan.
Cardiovasc J S Afr; 2004; 15(2):96-7. PubMed ID: 15148548
[No Abstract] [Full Text] [Related]
27. [Candesartan, angiotensin II receptor antagonist].
Sasaguri M; Arakawa K
Nihon Rinsho; 2000 Feb; 58 Suppl 2():144-8. PubMed ID: 11028310
[No Abstract] [Full Text] [Related]
28. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
Hoy SM; Keating GM
Am J Cardiovasc Drugs; 2010; 10(5):335-42. PubMed ID: 20860416
[TBL] [Abstract][Full Text] [Related]
29. [Angiotensin II receptor antagonists in arterial hypertension: new clinical evidence with candesartan].
Mancia G; Turri C; Magnoni M; Grassi G
Cardiologia; 1999 Dec; 44 Suppl 1(Pt 1):439-42. PubMed ID: 12497948
[No Abstract] [Full Text] [Related]
30. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
Sever PS
Blood Press Suppl; 2000; 1():19-22. PubMed ID: 11059631
[TBL] [Abstract][Full Text] [Related]
31. What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension?
Ruggenenti P; Remuzzi G
Nat Clin Pract Nephrol; 2006 May; 2(5):250-1. PubMed ID: 16932436
[No Abstract] [Full Text] [Related]
32. Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension.
Sasamura H; Kitamura Y; Nakamura M; Ryuzaki M; Saruta T
Clin Exp Hypertens; 2006 Jul; 28(5):511-20. PubMed ID: 16820347
[TBL] [Abstract][Full Text] [Related]
33. [Prevention of hypertension by drugs and immunization against angiotensin II].
Mitsuyama S
Nihon Naika Gakkai Zasshi; 2011 Feb; 100(2):446-52. PubMed ID: 21400884
[No Abstract] [Full Text] [Related]
34. Candesartan: widening indications for this angiotensin II receptor blocker?
Mendis B; Page SR
Expert Opin Pharmacother; 2009 Aug; 10(12):1995-2007. PubMed ID: 19563275
[TBL] [Abstract][Full Text] [Related]
35. [Focus on compliance. Rapid goal attainment in hypertension].
Riem L
MMW Fortschr Med; 2011 Jan; 153(4):51. PubMed ID: 22165621
[No Abstract] [Full Text] [Related]
36. Role of the renin-angiotensin system in hypertension in the elderly.
Nagano M; Higaki J; Mikami H; Ogihara T
Blood Press Suppl; 1994; 5():130-3. PubMed ID: 7889195
[TBL] [Abstract][Full Text] [Related]
37. Expanded roles of the renin-angiotensin system.
Fukuda D; Sata M
Hypertens Res; 2013 Jul; 36(7):586-7. PubMed ID: 23575385
[No Abstract] [Full Text] [Related]
38. [CHARM].
Momomura S
Nihon Rinsho; 2006 Aug; 64 Suppl 6():431-6. PubMed ID: 16981575
[No Abstract] [Full Text] [Related]
39. [EFFECTIVE data. New effectiveness dimensions in antihypertensive combination therapy].
MMW Fortschr Med; 2011 Jan; 153(4):50. PubMed ID: 22165620
[No Abstract] [Full Text] [Related]
40. Drug dosing for renoprotection: maybe it's time for a drug efficacy-safety score?
de Zeeuw D; Lambers-Heerspink H
J Am Soc Nephrol; 2009 Apr; 20(4):688-9. PubMed ID: 19279124
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
